Abortion pill restrictions hinder treatments for uterine conditions

The short version

• Medications including mifepristone, proven to shrink uterine fibroids by up to 50%, face mounting legal challenges and political opposition.[PBS NewsHour]
• Uterine fibroids affect 70% of white women and over 80% of Black women by age 50, causing severe pain and bleeding.[PBS NewsHour]
• The Trump administration launched a review of mifepristone as anti-abortion groups lobby for restrictions, while Florida, Texas, and Louisiana pursue lawsuits.[PBS NewsHour]
• Medical researchers caution that political stigma surrounding abortion drugs risks stalling clinical investment and therapeutic access for women's health conditions.[PBS NewsHour]

Key facts

• Mifepristone has been approved in the United States for abortion for more than 25 years and used safely by over 7.5 million women.[PBS NewsHour]
• Uterine fibroids affect 70 percent of white women and more than 80 percent of Black women by age 50.[PBS NewsHour]
• Global studies indicate that mifepristone and a similar drug can shrink uterine fibroids by up to 50 percent.[PBS NewsHour]
• The Trump administration launched a review of mifepristone earlier this year amid lobbying by anti-abortion groups.[PBS NewsHour]
• Florida, Louisiana, and Texas are suing to restrict access to mifepristone, and Louisiana classified it as a controlled substance two years ago.[PBS NewsHour]

Sources

Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.

• How abortion drug restrictions make it harder to treat other conditionsPBS NewsHour - Politics